A phase I, open-label, single-dose, crossover study to evaluate the relative bioavailability (rBA) and effect of food on New Pediatric Formulation of Idelalisib

Trial Profile

A phase I, open-label, single-dose, crossover study to evaluate the relative bioavailability (rBA) and effect of food on New Pediatric Formulation of Idelalisib

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Waldenstrom's macroglobulinaemia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 29 Mar 2018 New trial record
    • 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top